Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.
A significant reduction in plasma high density lipoprotein (HDL) cholesterol is a recognised consequence of treatment with probucol. By contrast, fibrate therapy in general has the opposite effect. We report two cases where the combination of probucol and a fibrate led to profoundly reduced plasma levels of HDL cholesterol associated with very low levels of apolipoprotein A-I (apoA-I). In the first, bezafibrate was added to probucol, and in the second, probucol added to a combination of simvastatin and fenofibrate. In both cases, plasma levels of HDL and apoA-I returned towards normal after discontinuation of one or both drugs, indicating that the reduction was reversible.
Murphy
M J
MJ
Institute of Biochemistry, Royal Infirmary, Glasgow, UK.
Duncan
A
A
Vallance
B D
BD
Packard
C J
CJ
O'Reilly
D S
DS
D000328:Adult; D000924:Anticholesteremic Agents / Q000009:adverse effects*; D001629:Bezafibrate / Q000009:adverse effects*; D008076:Cholesterol, HDL / Q000097:blood*; D004347:Drug Interactions; D005260:Female; D011345:Fenofibrate / Q000009:adverse effects*; D006801:Humans; D007009:Hypolipoproteinemias / Q000139:chemically induced*; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives*; D008297:Male; D008875:Middle Aged; D011341:Probucol / Q000009:adverse effects*; D019821:Simvastatin
D000924:Anticholesteremic Agents; D008076:Cholesterol, HDL; D008148:Lovastatin; D019821:Simvastatin; D011341:Probucol; D011345:Fenofibrate; D001629:Bezafibrate